The transradial route is increasingly used as an access site in percutaneous coronary interventions, as it is considered equivalent to transfemoral approach in terms of efficacy but with a decreased vascular complication risk. Information concerning the efficacy and safety of transulnar approach is sparse. This is a prospective, randomized, investigator-initiated study to compare transradial versus transulnar approach as a default strategy for coronary angiography, ad-hoc or elective percutaneous coronary intervention (PCI). Consecutive eligible patients with an indication for coronary angiography, will be randomized after written informed consent in a 1:1 ratio to either transradial or transulnar access. Assessment of angiographic and procedural characteristics(including amount of contrast medium, arterial access, fluoroscopy and procedural time), as well as any vascular or other peri-procedural complications of the cases enrolled, will be performed. After hospital discharge, all patients will return at Day 60 ±5 days for Doppler ultrasound assessment of the forearm vessels and documentation of major adverse cardiovascular events (defined as death, myocardial infarction, target vessel revascularization and stroke. Coronary angiography patients will be additionally randomized in a 1:1 ratio to either 2500 or 5000 IU of unfractioned heparin.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
572
Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
Transradial arterial access for coronary angiography,ad-hoc or elective PCI
Patras University Hospital
Pátrai, Rion, Greece
RECRUITINGSuccessful arterial access free from need for crossover and free from vascular or coronary ischemic complications (MACEs)within 60± days
MACEs are considered both vascular and coronary ischemic complications. Vascular complications include arterial occlusion, local arterial perforation, compartment syndrome, pseudoaneurysm, fistula formation, major bleeding, hematoma of at least 10cm length, or any vascular damage requiring prolonged hospitalization or intervention. Coronary ishcemic complications include cardiac death, non fatal myocardial infarction, urgent repeat revascularization and stroke.
Time frame: The primary end point will be assessed within 60±5 days after randomization
Fluoroscopy time
Fluoroscopy time (in seconds) assessed within 1 minute after the end of coronary angiography or coronary intervention
Time frame: Fluoroscopy time will be assessed within 1 minute after the end of coronary angiography or coronary intervention
Amount of contrast medium
Volume of contrast medium (ml) will be assessed within 1 minute after the end of coronary angiography or coronary intervention
Time frame: The amount of contrast medium will be assessed within 1 minute after the end of coronary angiography or coronary intervention
Vascular complication defined as post-procedural occlusion, perforation, pseudo-aneurysm, fistula or hematoma formation
Vascular complication (defined as post-procedural occlusion, perforation, pseudo-aneurysm, fistula or hematoma formation of at least 10 cm length, compartment syndrome) will be assessed 6 hours after the end of coronary angiography or intervention
Time frame: Vascular complication will be assessed 6 hours after the end of coronary angiography or intervention
Procedural duration (defined as the sum of arterial access, coronary angiography and coronary intervention duration)
Procedural duration (defined as the sum of arterial access, coronary angiography and coronary intervention duration)will be assessed within 1 minute after the end of coronary angiography or coronary intervention
Time frame: Procedural duration will be assessed within 1 minute after the end of coronary angiography or coronary intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.